ASX Announcements

Aug 2022
Aug 10th, 2022
Starpharma signs new DEP® agreement with MSD

Jul 2022
Jul 29th, 2022
Quarterly Activities Report & Appendix 4C
Jul 20th, 2022
VIRALEZE Protects Against Omicron in Viral Challenge
Jul 6th, 2022
Change in Substantial Holder

Jun 2022
Jun 30th, 2022
VIRALEZE™ relaunched by LloydsPharmacy in the UK
Jun 27th, 2022
Starpharma signs expanded DEP® research agreement with US Biopharma Co
Jun 3rd, 2022
Shareholder Newsletter

May 2022
May 27th, 2022
Appendix 2A
May 27th, 2022
Appendix 3H
May 18th, 2022
SPL7013 in VIRALEZE™ virucidal against influenza A and B

Apr 2022
Apr 29th, 2022
Quarterly Cashflow and Activities Report
Apr 28th, 2022
Change in Substantial Holder
Apr 27th, 2022
Starpharma to present DEP® at Boston ADC summit
Apr 1st, 2022
Starpharma appoints Dr Jeff Davies and Appendix 3X
Apr 1st, 2022
VIRALEZE™ to relaunch in the UK

Mar 2022
Mar 17th, 2022
Appendix 2A
Mar 4th, 2022
Response to media article
Mar 1st, 2022
SPL7013 in VIRALEZE™ virucidal against Omicron

Feb 2022
Feb 24th, 2022
Dr Jeff Davies appointed as non-executive director
Feb 21st, 2022
Starpharma Interim Report and Half-Year Financial Results
Feb 4th, 2022
VIRALEZE™ Saudi Arabia Distribution - supplementary information
Feb 4th, 2022
Change in Substantial Holder
Feb 3rd, 2022
VIRALEZE™ sales and distribution in Saudi Arabia and GCC
Feb 1st, 2022
Appendix 3H
Feb 1st, 2022
Appendix 2A
Feb 1st, 2022
Appendix 2A

Jan 2022
Jan 28th, 2022
Quarterly Cashflow and Activities Report
Jan 20th, 2022
Starpharma receives $7.7M R&D tax incentive refund